Antimicrobial and antiurease activities of newly synthesized morpholine derivatives containing an azole nucleus

Hakan Bektas • Şule Ceylan • Neslihan Demirbaş • Şengül Alpay-Karaoğlu • Bahar Bilgin Sökmen

Received: 24 June 2012 / Accepted: 25 October 2012 / Published online: 29 November 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract 2-[(6-(Morpholin-4-yl)pyridin-3-ylamino)acetohydrazide (4) was obtained starting from 6-morpholin-4-ylpyridin-3-amine (2) via the formation of ester (3) and then converted to the corresponding Schiff bases (5, 6) with the reaction with aromatic aldehydes. The carbothioamide (9), obtained from the reaction of hydrazide with phenylisothiocyanate, was converted to the corresponding 1,2,4-triazole (11) and 1,3,4-oxadiazole (12) derivatives by the treatment with NaOH or H2SO4, respectively. The cyclocondensation of 9 with 4-chlorophenacyl bromide or ethyl bromoacetate produced the corresponding 1,3-thiazole (10) or 1,3-thiazolidine derivatives (13), respectively. Antimicrobial and antiurease activities of newly synthesized compounds were investigated. Some of them were found to be active on M. smegmatis, and they displayed activity toward C. albicans and S. cerevisiae in high concentration. Compound 10 proved to be the most potent showing an enzyme inhibition activity with an IC50 = 2.37 ± 0.19 μM.

Keywords Morpholine • 1,2,4-Triazole • 1,3,4-Oxadiazole • Mannich base • Antimicrobial activity • Antiurease activity

Introduction

Urea amidohydrolases (ureases) have been known as a class of large heteropolymeric enzymes with the active site containing two nickel (II) atoms and to accelerate hydrolysis of urea to ammonia gas with the reaction rate at least 1014 over the spontaneous reaction. Ureases are widely distributed in nature and are found in a variety of plants, algae, fungi, and bacteria (Kot et al., 2010). Medically, bacterial ureases have been reported as important virulence factors implicated in the pathogenesis of many clinical conditions such as pyelonephritis, hepatic coma, peptic ulceration, and the formation of injection-induced urinary stones and stomach cancer. The catalytic mechanism of their action has been believed to be the same of all urease inhibitors in which the amino acid sequences of the active site are principally conserved (Xiao et al., 2010). The active site of the native enzyme binds three water molecules and a hydroxide ion bridged between two nickel ions (Bachmeier et al., 2002). In the course of enzymatic reaction, urea replaces these three water molecules and bridges the two metal ions. The surrounding by a hydrogen-bonding network strongly activates the inert urea molecule; it is subsequently attacked by the hydroxide ion, forming a tetrahedral transition state. As a result, ammonia is released from the active site followed by the negatively charged carbamate (Adil et al., 2011). The latter decomposes rapidly and spontaneously, yielding a second molecule of ammonia. The ammonia generated may cause
Urease is also indispensable for colonization of human gastric mucosa by *Helicobacter pylori*. The ammonia produced has been shown to be toxic for various gastric cell lines. Furthermore, urease activity was proposed to damage the gastric epithelium via its interaction with the immune system by stimulating an oxidative burst in human neutrophils (Ito *et al*., 1998). H$_2$O$_2$ generated in this oxidative burst probably reacts with ammonia and chloride to yield the toxic monochloramine (Kot *et al*., 2010). Finally, the ammonia may reach the serum and contribute to symptoms of hepatic encephalopathy in patients suffering from cirrhosis. Apart from ammonia, the carbon dioxide generated by urea hydrolysis may play a significant role for survival of *H. pylori* in the gastric mucosa (Cobena *et al*., 2008; Mirosława *et al*., 2010; Xiao *et al*., 2010; Khan *et al*., 2010a, b; Ito *et al*., 1998; Keri *et al*., 2002; Ashiraleeva and Kleiner, 2003).

Moreover, urea constitutes the predominant source of nitrogen containing fertilizers used in agriculture, accounting for 50% of the total world fertilizer nitrogen consumption. However, the efficiency of urea is decreased by its hydrolysis with the enzyme urease to ammonia gas in soil. Besides the economic impact for farmers, NH$_3$ lost to the atmosphere from applied urea causes eutrophication and acidification of natural ecosystems on a regional scale (Cobena *et al*., 2008).

Several classes of compounds have been reported as the agents having antiurease activity; among them hydroxamic acids are the best recognized urease inhibitors (Adil *et al*., 2011). Phosphoramidates, another class of antiurease agents, have been reported as the most potent compounds (Amtul *et al*., 2002; Kot *et al*., 2001). However, the teratogenicity of hydroxamic acid in rats and degradation of phosphoramidates at low pH (Adil *et al*., 2011, Domínguez *et al*., 2008; Kreybig *et al*., 1968) restrict their use as a drug in vivo. Another class of compounds showing enzyme’s inhibitory activity is polyphenols such as galloacetin that is a polyphenol extracted from green tea and quercetin, a naturally occurring flavonoid having anti- *H. pylori* activity (Matsubara *et al*., 2003; Shin *et al*., 2005).

In addition, some 1,2,4-triazoles, 1,3,4-oxadiazoles, and 1,3,4-thiadiazoles have also been reported as the compounds possessing antiurease activity (Amtul *et al*., 2004; Aktay *et al*., 2009; Bekircan *et al*., 2008). Recently, some complexes of Schiff bases with metal ions showed significant inhibitory activities against urease (Shi *et al*., 2007; You *et al*., 2010) along with other metal complexes (Cheng *et al*., 2009). However, owing to the presence of heavy metal atoms, these types of compounds can inflict toxic effects on human body (Duruibe *et al*., 2007); hence, such molecules cannot be used as drugs.

During the recent decades, the human population being afflicted with life-threatening infectious diseases caused by multidrug-resistant Gram-positive and Gram-negative pathogen bacteria has been increasing at an alarming scale around the world as a result of antimicrobial resistance. In spite of the wide range of antimicrobial drugs with different mechanisms of action used for the treatment of microbial infections either alone or in combination and also the existence of many compounds used in different phases of clinical trials, microbial infections have been posing a worldwide problem. There is already evidence that antimicrobial resistance is associated with an increase in mortality (Bayrak *et al*., 2010a, b, 2009a, b; Demirbas *et al*., 2009). The growing number of reports of antibiotic resistance worldwide has led to fears that some lethal human pathogens, such as *Mycobacterium tuberculosis*, will soon become untreatable (Dye and Williams, 2009; Dye and Phill, 2006; Koca *et al*., 2005; Zalavadiya *et al*., 2009). Tuberculosis (TB) causes the death of approximately three million patients in the world every year. These numbers make TB one of the leading infectious causes of death, eclipsed only by AIDS. Synthetic drugs for treating TB have been available for over half a century, but incidences of the disease continue to be on the rise worldwide. The causative organism, *Mycobacterium tuberculosis*, is a tremendously successful colonizer of the human host and is estimated to have latently infected approximately one-third of humanity. A growing number of immunocompromised patients are attributed to cancer chemotherapy, organ transplantation, and HIV infection, which are the major factors contributing to this increase. Therefore, it is necessary to search for and synthesize new classes of antimicrobial compounds that are effective against pathogenic microorganisms that have developed resistance to the antibiotics (Dye and Williams, 2009; Dye and Phill, 2006; Koca *et al*., 2005; Zalavadiya *et al*., 2009; Bayrak *et al*., 2010a, b).

In the field of medicinal chemistry, azoles belong to a class of antimicrobial agents that are widely used and studied because of their safety profile and high therapeutic index. Ribavirin, rizatriptan, alprazolam, vorozole, letrazole, and anastrozole are the best examples of drugs containing 1,2,4-triazole moiety (Ashok *et al*., 2007; Rao *et al*., 2006; Hancu *et al*., 2007; Cai *et al*., 2007). Among azole-based drugs, conazoles, such as itraconazole, fluconazole, voriconazole, and ravuconazole constitute a major class being used for the treatment of fungal infections (Yu *et al*., 2007; Gupta *et al*., 2007; Schiller and Fung, 2007). Another important pharmacophore group is the morpholine nucleus incorporated in a wide variety of therapeutically important drugs, one of which is linezolid which belongs to the oxazolidinone class of antibiotics and is used for the treatment of infections caused by gram-positive bacteria (Wyrzykiewicz *et al*., 2006; Dixit *et al*., 2005;
Raparti et al., 2009; Bektas et al., 2010, 2012; Bayrak et al., 2009a, b). In addition, 4-phenylmorpholine derivatives have been reported to possess antimicrobial, anti-inflammatory, and central nervous system activities (Dixit et al., 2006). Oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action that involves early inhibition of bacterial protein synthesis. This class of compounds is particularly active against gram-positive organisms. Oxazolidinones are thought not to be cross-resistant with other types of antibiotics because of their different action mechanisms, which include interaction with the bacterial ribosome to inhibit bacteria. (Zheng et al., 2010; Giera et al., 2006; Das et al., 2005; Gage et al., 2000; Cui et al., 2005). Hence, oxazolidinone class of antibacterial compounds attracted considerable attention of a number of research groups during the last decade to get more efficacious and less toxic drug (Srivastava et al., 2008).

Thiazolidinone derivatives have been further reported to possess diverse pharmacological properties, such as antibacterial, antifungal, anticonvulsant, anticancer, anti-tuberculosis, and antihuman immunodeficiency virus type 1 (HIV-1) activities. Thiazolidinones are novel inhibitors of the bacterial enzyme MurB, a precursor acting during the biosynthesis of peptidoglycan as an essential component of the cell wall of both gram-positive and gram-negative bacteria. (Bonde and Gaikwad, 2004; Aridoss et al., 2007; Küçükgüzel et al., 2002; Capan et al., 1999; Barreca et al., 2001; Andres et al., 2000; El-Gaby et al., 2009).

Results and discussion

The synthetic route for the newly synthesized compounds (3–13) is illustrated and outlined in Schemes 1 and 2. The identification and synthesis of combinational chemotherapeutic drugs with different mechanisms of action and with few side effects are an important part of the efforts to overcome antimicrobial resistance (Bayrak et al., 2010a, b). A recent survey of novel small-molecule therapeutics has revealed that the majority of the drugs results from an analog-based approach and that their market share represents two-thirds of all drug sales (Vicini et al., 2008).

In the present study, as a part of our ongoing study on the synthesis of bioactive hybrid molecules, we aimed to obtain the far derivatives of linezolid. It was reported that SAR studies of linezolid demonstrated a high tolerance for structural variation at the 4-position of the phenyl ring (Weidner-Wells et al., 2002). In the structures of the newly synthesized compounds, the phenyl ring substituted by pyridine and oxazolidinone scaffold by other azole rings such as 1,3-thiazole, 1,3-thiazolidinone, 1,2,4-triazole, 1,3,4-thiadiazole, and 1,3,4-oxidiazole nucleus.

Scheme 1 Synthetic pathway for the preparation of compounds 1–6. i morpholine, ii Pd/C catalyst, H2NNH2, iii BrCH2CO2Et, iv H2NNH2, v BrC6H4CHO, vi C6H5CH=CHCHO.
hydrazide function, whereas the signals due to ester group disappeared in the NMR spectrum. The treatment of hydrazide, 4 with aromatic aldehydes, namely, 4-bromobenzaldehyde and cinnamaldehyde produced the corresponding Schiff bases, compounds 5 and 6. In the 1H NMR spectra of these compounds, the signal derived from NH2 group disappeared; instead, new signals originated from aldehyde moiety were recorded at the related chemical shift values in the 1H NMR and 13C NMR spectra. Moreover, these compounds (5 and 6) exhibited EI-MS and elemental analysis data consistent with the proposed structures.

The synthesis of 5-[(6-morpholin-4-ylpyridin-3-yl)amino]methyl]-1,3,4-oxadiazole-2-thiol (7) was carried out from the reaction of hydrazide 4 with carbon disulfide in the presence of potassium hydroxide. An evidence for the formation of 7 is the absence of the signals corresponding to hydrazide function in the FT-IR and 1H NMR spectra. The D2O exchangeable signal observed at 13.45 ppm was attributed to the SH proton located at the position-2 of 1,3,4-oxadiazole ring. The reaction of 7 with phenylpiperazine in the presence of formaldehyde afforded the corresponding Mannich base, 5-[(6-morpholin-4-ylpyridin-3-yl)amino]methyl]-3-[(4-phenylpiperazin-1-yl)methyl]-1,3,4-oxadiazole-2(3H)-thione (8). In NMR spectra of 7, the presence of the peaks belonging to 4-phenylpiperazine nucleus confirmed the Mannich reaction.

The synthesis of N0-[(5-(4-chlorophenyl)-3-phenyl-1,3-thiazol-2(3H)-ylidene)-2-[(6-morpholin-4-ylpyridin-3-yl)amino]acetohydrazide (10) obtained from the cyclocondensation reaction between 4-chlorophenacyl bromide

**Scheme 2** Synthetic pathway for the preparation of compounds 7–13. i CS2/KOH, ii phenyl piperazine, iii PhNCS, iv BrCH2CO2Et, v NaOH, vi H2SO4, vii BrCH2CO2Et
and compound 9 that was obtained by the treatment of hydrazide 4 with phenylisothiocyanate. On the other hand, the treatment of the same intermediate 9 with ethyl bromoacetate resulted in the formation of 2-[(6-morpholin-4-ylpyridin-3-yl)amino]-N-([4-oxo-3-phenyl-1,3-thiazolidin-2-yldene]acetohydrazide 13. The structures of these compounds were confirmed on the basis of FT-IR, EI-MS, $^1$H NMR, $^{13}$C NMR spectroscopic methods, and elemental analysis.

The basic treatment of intermediate 9 afforded 5-[(6-morpholin-4-ylpyridin-3-yl)methyl]-4-phenyl-4H-1,2,4-triazole-3-thiol (11), while the cyclization of 9 in acidic media yielded 5-[(6-morpholin-4-ylpyridin-3-yl)methyl]-N-phenyl-1,3,4-thiadiazol-2-amine (12). In the $^1$H NMR spectrum of compound 11, the signal due to SH group was recorded at 13.91 ppm as an evidence of intramolecular cyclization. This group was seen at 2,857 cm$^{-1}$ in the FT-IR spectrum of compound 11. Two NH signals were recorded at 6.04 and 10.23 ppm as D$_2$O exchangeable peaks in the $^1$H NMR spectrum of compound 12. In the $^{13}$C NMR spectra of compounds 11 and 12, other signals belonging to 1,2,4-triazole or 1,3,4-thiadiazole nuclei resonated at the chemical shift values consistent with the literature (Bektas et al., 2010, 2012). Furthermore, [M]$^+$ ion peaks were observed at the related m/z values supporting the proposed structures. In addition, these compounds gave reasonable elemental analysis data.

The newly synthesized compounds 3–13 were evaluated in vitro for their antimicrobial activities. The results are presented in the Table 1. Among the compounds tested, compound 8, which contains different heterocyclic moieties such as morpholine, pyridine, piperazine, and 1,3,4-oxadiazone important antimicrobial activity, was found to be active against all the microorganisms. All compounds except compounds 6, 7, 10, and 13 exhibited activity toward Mycobacterium smegmatis (Ms), a nonpigmented, rapidly growing mycobacterium and an atypical tuberculosis factor leading to morbidity and mortality. The highest Ms activity with the MIC value 15.6 μg/mL was observed for compound 12 that is a 1,2,4-triazole derivative containing morpholine and pyridine nuclei as well. All the tested compounds were found to be active on yeast like fungi, Candida albicans (Ca) and Saccharomyces cerevisiae (Sc), in high concentrations with the MIC values of 500 or 1,000 μg/mL, whereas all compounds, except compound 8, displayed no activity against gram-negative bacterial strain. In contrast to other compounds, compound 12 demonstrated a low activity against Pseudomonas aeruginosa (Pa), a gram-negative bacillus.

Almost all the compounds showed moderate-to-good urease inhibitory activity (Table 2). The inhibition was increased with increasing compound concentration. Potent compound have their activities in the range of 2.37–13.23 μM. Lower IC$_{50}$ values indicate higher enzyme inhibitor activity. Compound 10 proved to be the most potent showing an enzyme inhibition activity with an IC$_{50} = 2.37 \pm 0.19$ μM. The least active compound 3 had an IC$_{50} = 13.23 \pm 2.25$ μM.

### Table 1

| Comp. no | Microorganisms and minimal inhibition concentration |
|----------|---------------------------------------------------|
|          | Ec       | Yp       | Pa       | Ef       | Sa       | Bc       | Ms       | Ca       | Sc       |
| 3        | –        | –        | –        | –        | –        | 125      | 1,000    | 1,000    |          |
| 4        | –        | –        | –        | –        | –        | 125      | 500      | 1,000    |          |
| 5        | –        | –        | –        | –        | –        | 31.3     | 1,000    | 1,000    |          |
| 6        | –        | –        | –        | –        | –        | –        | 500      | 1,000    |          |
| 7        | –        | –        | –        | –        | –        | –        | 500      | 1,000    |          |
| 8        | 62.5     | 62.5     | 62.5     | 31.3     | 31.3     | 62.5     | 125      | 1,000    | 1,000    |
| 9        | –        | –        | –        | –        | –        | 125      | 1,000    | 1,000    |          |
| 10       | –        | –        | –        | –        | –        | –        | 500      | 1,000    |          |
| 11       | –        | –        | –        | –        | –        | 125      | 500      | 1,000    |          |
| 12       | –        | –        | 500      | –        | –        | 15.6     | 500      | 1,000    |          |
| 13       | –        | –        | –        | –        | –        | –        | 500      | 1,000    |          |
| Amp.     | 8        | 32       | >128     | 2        | 2        | <1       |          |          |          |
| Str.     | 4        |          |          |          |          |          |          |          |          |
| Flu.     | <8       | <8       |          |          |          |          |          |          |          |

Ec: Escherichia coli ATCC 25922, Yp: Yersinia pseudotuberculosis ATCC 911, Pa: Pseudomonas aeruginosa ATCC 43288, Ef: Enterococcus faecalis ATCC 29212, Sa: Staphylococcus aureus ATCC 25923, Bc: Bacillus cereus 702 Roma, Ms: Mycobacterium smegmatis ATCC 607, Ca: Candida albicans ATCC 60193, Sc: S. cerevisiae RSKK 251, Amp.: Ampicillin, Str.: Streptomisin, Flu.: Fluconazole
Compounds IC₅₀ (µM)a

|    |      |
|----|------|
| 3  | 13.23 ± 2.25 |
| 4  | 7.92 ± 1.43  |
| 5  | 6.87 ± 0.06  |
| 6  | 8.29 ± 2.30  |
| 7  | 7.01 ± 0.68  |
| 8  | 4.99 ± 0.59  |
| 9  | 8.07 ± 1.25  |
| 10 | 2.37 ± 0.19  |
| 11 | 4.77 ± 0.92  |
| 12 | 6.05 ± 1.19  |
| 13 | 4.46 ± 0.22  |

a Mean ± SD

Conclusion

In this study, the synthesis of some morpholine derivatives (3–13) were performed, some of which contain an azole moiety, and their structures were confirmed by IR, ¹H NMR, ¹³C NMR, Mass spectroscopic, and elemental analysis techniques. In addition, the newly synthesized compounds were screened for their antimicrobial and antiurease activities. Some of them were found to possess activity on M. smegmatis, C. albicans ATCC, and S. cerevisiae. Furthermore, all the compounds exhibited moderate-to-good antiurease activity.

Experimental

Chemistry

General information for chemicals

All the chemicals were purchased from Fluka Chemie AG Buchs (Switzerland) and used without further purification. Melting points of the synthesized compounds were determined in open capillaries on a Büchi B-540 melting point apparatus and are uncorrected. Reactions were monitored by thin-layer chromatography (TLC) on silica gel 60 F254 aluminum sheets. The mobile phase was ethanol:ethyl acetate, 1:1, and detection was made using UV light. FT-IR spectra were recorded as potassium bromide pellets using a Perkin Elmer 1600 series FTIR spectrometer. ¹H NMR and ¹³C NMR spectra were registered on DMSO-d₆ on a BRUKER AVENUE II 400 MHz NMR Spectrometer (400.13 MHz for ¹H and 100.62 MHz for ¹³C). The chemical shifts are given in ppm relative to Me₄Si as an internal reference; J values are given in Hz. The elemental analysis was performed on a Costech Elemental Combustion System CHNS-O elemental analyzer. All the compounds gave C, H, and N analysis results within ±0.4 % of the theoretical values. The mass spectra were obtained on a Quattro LC–MS (70 eV) Instrument. Compounds 1 and 2 are available commercially.

Synthesis of compound 3

Ethylbromoacetate (10 mmol) was added to the mixture of compound 2 (10 mmol), and triethylamine (10 mmol) was added dropwise in dry tetrahydrofuran at 0–5 °C. Then, the reaction content was allowed to reach to room temperature and stirred for 11 h (the progress of the reaction was monitored by TLC). The precipitated triethylammonium salt was removed by filtration. After evaporating the solvent under reduced pressure, a brown solid appeared. This crude product was recrystallized from ethanol–water (1:2) to afford the desired product.

Ethyl N-(6-morpholin-4-ylpyridin-3-yl)glycinate (2)

Yield (1.27 g, 50 %); m.p. 83–84 °C; IR (KBr, v, cm⁻¹): 3.378 (NH), 1.725 (C=O), 1.575 (C=N), 1.118 (C–O); ¹H NMR (DMSO-d₆, δ ppm): 1.17 (t, 3H, CH₃, J = 7.4 Hz), 3.18 (t, 4H, 2NCH₂, J = 4.8 Hz), 3.69 (t, 4H, 2OCH₂, J = 4.4 Hz), 3.84 (d, 2H, NHCH₂, J = 6.4 Hz), 4.08 (q, 2H, OCH₂CH₃, J = 7 Hz), 5.57 (t, 1H, NH, J = 6.8 Hz), 6.67 (d, 1H, arH, J = 9 Hz), 6.92–6.98 (m, 1H, arH), 7.56 (d, 1H, arH, J = 2.4 Hz); ¹³C NMR (DMSO-d₆, δ ppm): 14.83 (CH₃), 45.84 (NHCH₂), 47.40 (2NCH₂), 60.94 (CH₂OCH₂), 66.74 (2OCH₂), arC: [108.94 (CH), 123.74 (CH), 132.35 (CH), 138.22 (C), 153.34 (C)], 172.08 (C=O); LC–MS: m/z (%) 266.257 [M+H]+ (85), 164.12 (94); Anal.calcd (%) for C₁₇H₂₆N₃O₃: C, 58.85; H, 7.22; N, 15.84. Found: C, 58.65; H, 7.28; N, 15.85.

Synthesis of compound 4

Hydrazide hydrate (25 mmol) was added to the solution of compound 2 (10 mmol) in absolute ethanol, and the mixture was allowed to reflux for 7 h. On cooling the reaction mixture to room temperature, a white solid appeared. The crude product was filtered off and recrystallized from ethanol to give the desired compound 4.

2-[6-(Morpholin-4-yl)pyridin-3-ylamino] facetoxydrazide (4)

Yield (2.23 g, 89 %); m.p. 175–177 °C; IR (KBr, v, cm⁻¹): 3341, 3301, 3189 (NH₂+NH), 1.658 (C=O), 1.578 (C=N), 1.118 (C–O); ¹H NMR (DMSO-d₆, δ ppm): 3.14 (t, 4H, N–2CH₂, J = 4.8 Hz), 3.77 (t, 4H, O–2CH₂, J = 4.8 Hz), 4.00 (d, 2H, N–CH₂, J = 6.4 Hz), 4.22 (s, 2H, NH₂), 5.42

 Springer
The solution of compound 4-3-ylamino]acetohydrazide (desired compound. filtered off and recrystallized from ethanol to obtain the was refluxed with appropriate aldehyde (10 mmol) for 6 h.

The synthesis of compounds 5 and 6

The solution of compound 4 (10 mmol) in absolute ethanol was refluxed with appropriate aldehyde (10 mmol) for 6 h. Then, the reaction content was allowed to cool to room temperature, and a solid appeared. This crude product was filtered off and recrystallized from ethanol to obtain the desired compound.

N-(4-Bromobenzylidene)-2-[6-(morpholin-4-yl)pyridin-3-ylamino]acetohydrazide (5)

Yield (3.43 g, 82 %); m.p. 163–164 °C; IR (KBr, v, cm⁻¹): 3,307 (2NH), 1,687 (C=O), 1,590 (C=N), 1,121 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.20 (brs, 4H, N–2CH₂), 3.73 (brs, 4H, O–2CH₂), 4.20 (brs, 2H, CH₂), 6.73 (d, 1H, arH, J = 8.6 Hz), 6.99–7.12 (m, 1H, NH), 7.63 (d, 6H, arH, J = 6.2 Hz), 8.91 (s, 1H, N=CH), 11.58 (s, 1H, NH); ¹³C NMR (DMSO-d₆, δ ppm): 45.93 (CH₂), 56.72 (N–2CH₂), 66.61 (O–2CH₂), arC: [123.20 (C), 124.90 (C), 129.66 (CH), 130.01 (CH), 130.73 (CH), 130.98 (2CH), 132.51 (2CH), 136.25 (C), 138.16 (C), 132.62 (N=CH), 166.12 (C=O); LC–MS: m/z (%) 418.66 [M]+ (78), 265.12 (28); Anal. calcld (%) for C₁₈H₁₅N₅O₂S: C, 51.69; H, 4.82; N, 16.74. Found: C, 51.60; H, 4.75; N, 16.80.

2-[[6-(Morpholin-4-yl)pyridin-3-ylamino]-N-(3-phenylallylidene)acetohydrazide (6)

Yield (3.18 g, 87 %); m.p. 194–195 °C; IR (KBr, v, cm⁻¹): 3,308 (2NH), 1,666 (C=O), 1,554 (C=N), 1,120 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.19 (brs, 4H, N–2CH₂), 3.67 (brs, 4H, O–2CH₂), 4.08 (d, 2H, CH₂, J = 5.2 Hz), 5.46 (s, 1H, CH), 6.69 (d, 1H, CH, J = 8.2 Hz), 6.99 (d, 3H, arH±NH, J = 3.2 Hz), 7.35 (d, 3H, arH, J = 7.4 Hz), 7.61 (brs, 3H, arH), 7.91 (s, 1H, NH), 11.42 (s, 1H, NH); ¹³C NMR (DMSO-d₆, δ ppm): 47.48 (CH₂), 56.72 (N–2CH₂), 66.75 (O–2CH₂), arC: [125.83 (CH), 126.20 (CH), 127.76 (CH), 129.53 (CH), 132.51 (CH), 136.56 (C), 138.42 (CH), 139.62 (CH), 146.75 (CH), 153.22 (C), 167.52 (C), 108.98 (CH), 123.84 (CH), 149.48 (N=CH), 172.00 (C=O); LC–MS: m/z (%) 365.66 [M]+ (75), 265.46 (56), 165.23 (90); Anal. calcld (%) for C₂₀H₁₅N₅O₂: C, 65.74; H, 6.34; N, 19.16. Found: C, 65.82; H, 6.36; N, 19.22.

Synthesis of compound 7

Compound 4 (10 mmol) and CS₂ (6.0 mL, 10 mol) were added to a solution of KOH (0.56 g, 10 mol) in 50 mL H₂O and 50 mL ethanol. The reaction mixture was refluxed for 3 h. After evaporating in reduced pressure to dryness, a solid was obtained. This was dissolved in 300 mL H₂O and acidified with conc. HCl. The precipitate was filtered off, washed with H₂O, and recrystallized from ethanol to afford the desired compound.

5-[[6-Morpholin-4-yl]pyridin-3-ylamino]methyl]-1,3,4-oxadiazole-2-thiol (7)

Yield (2.08 g, 71 %); m.p. 221–222 °C; IR (KBr, v, cm⁻¹): 3,299 (NH), 3,071 (Ar CH), 1,535 (C=N), 1,118 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.20 (s, 4H, N–2CH₂), 3.67 (s, 4H, O–2CH₂), 4.35 (brs, 2H, CH₂), 5.94 (bs, 1H, NH), 6.71 (d, 1H, arH, J = 7.4 Hz), 7.04 (d, 1H, arH, J = 9 Hz), 7.67 (s, 1H, arH), 13.45 (s, 1H, SH); ¹³C NMR (DMSO-d₆, δ ppm): 38.44–41.36 (DMSO-d₆+CH₂), 47.15 (N–2CH₂), 66.67 (O–2CH₂), arC: [109.22 (CH), 124.70 (CH), 132.04 (CH), 137.20 (C), 150.45 (C)], 163.10 (oxadiazole C-2), 178.54 (oxadiazole C-5); LC–MS: m/z (%) 293.45 [M]+ (45), 294.75 [M+1]+ (86), 165.23 (35); Anal. calcld (%) for C₁₂H₁₃N₈O₂S: C, 49.13; H, 5.15; N, 23.87, S, 10.93. Found: C, 49.25; H, 5.10; N, 23.90; S, 10.85.

Synthesis of compound 8

To the solution of corresponding compound 7 (10 mmol) in dichloromethane, formaldehyde (37 %, 1.55 mL) and phenyl piperazine (10 mmol) were added, and the mixture was stirred at room temperature for 3 h. After removing the solvent under reduced pressure, a solid was obtained. This crude product was treated with water, filtered off, and recrystallized from ethyl acetate/petroleum ether (1:2) to yield the desired compound.

5-[[6-Morpholin-4-yl]pyridin-3-ylamino]methyl]-3-[[4-phenylpiperazin-1-yl)methyl]-1,3,4-oxadiazole-2-thione (8)

Yield (3.79 g, 81 %); m.p. 87–88 °C; IR (KBr, v, cm⁻¹): 3,392 (NH), 1,599 (C=N), 1,118 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.14 (s, 4H, N–2CH₂), 3.79 (s, 4H, O–2CH₂), 4.51 (brs, 2H, CH₂), 4.86 (bs, 8H, 4CH₂), 5.01 (s, 2H, CH₂), 5.43 (bs, 1H, NH), 6.61 (m, 1H, arH), 6.90 (m, 3H, arH), 7.26 (m, 3H, arH), 8.03 (m, 1H, arH); ¹³C NMR (DMSO-d₆, δ ppm): 46.33(N–CH₂), 46.54 (N–CH₂), 49.52 (N–CH₂), 50.16 (N–CH₂), 50.59 (N–CH₂), 66.97 (O–2CH₂), 70.28 (2CH₂), arC: [107.98 (CH), 116.64 (2CH), 117.32 (CH), 120.39 (CH), 129.43 (2CH), 133.42 (C),
136.29 (CH), 151.39 (C), 156.61 (C), 173.47 (oxadiazole C-5); LC–MS: m/z (%) 466.85 \([M]^+\) (54), 476.18 [M+1]^+ (36), 215.45 (55); Anal.calcd (%) for C23H29N7O2S: C, 59.08; H, 6.25; N, 20.97, S, 8.30. Found: C, 58.72; H, 5.42; N, 22.80; S, 8.70. Cast: C, 58.72; H, 5.42; N, 22.80; S, 8.70. Yield (3.17 g, 87 %); m.p. 165–166

**Synthesis of compound 9**

The mixture of compound 4 (10 mmol) and phenylisothiocyanate (10 mmol) in absolute ethanol was refluxed for 6 h. On allowing the reaction content to be cooled to room temperature, a white solid was formed. This crude product was filtered off and recrystallized from ethylacetate to afford the desired compound.

2-\{[6-Morpholin-4-ylpyridin-3-yl]amino\}acetoyl-4-phenylhydrazinecarbothioamide (9)

Yield (3.16 g, 82 %): m.p. 171–172 °C; IR (KBr, v, cm⁻¹): 3,321 (2NH), 3,164 (2NH), 1,685 (C=O), 1,215 (C=S), 1,110 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.02 (bs, 4H, N–2CH₂), 3.66 (s, 4H, O–2CH₂), 4.06 (d, 2H, CH₂, J = 6 Hz), 6.92 (d, 2H, arH, J = 9.8 Hz), 7.26 (d, 2H, arH, J = 9.4 Hz), 7.75 (bs, 2H, arH), 9.55 (s, 1H, NH), 9.72 (bs, 1H, NH), 10.42 (s, 1H, NH); ¹³C NMR (DMSO-d₆, δ ppm): 45.32 (CH₂), 55.54 (N–2CH₂), 66.35 (O–2CH₂), arC: [101.52 (CH), 114.56 (CH), 125.83 (CH), 126.20 (CH), 128.24 (CH), 132.51 (CH), 136.56 (C), 138.42 (CH), 139.62 (CH), 146.75 (C), 153.22 (C)], 170.56 (C=O), 182.23 (C=S); LC–MS: m/z (%) 386.25 [M]^+ (68), 265.24 (66), 165.85 (87); Anal.calcd (%) for C₁₈H₁₈N₉O₂S: C, 55.94; H, 5.74; N, 21.75; S, 8.30. Found: C, 55.82; H, 5.82; N, 21.62; S, 8.42.

**Synthesis of compound 10**

4-Chlorophenacylbromide (10 mmol) and dried sodium acetate (16.4 g 200 mmol) was added to the solution of compound 9 in absolute ethanol, and the reaction mixture was refluxed for 7 h. Then, the mixture was cooled to room temperature, poured into ice-cold water under stirring, and left overnight in cold. The formed solid was filtered, washed with water three times and recrystallized from ethanol to afford compound 10.

N'-(5-(4-Chlorophenyl)-3-phenyl-1,3-thiazol-2(3H)-yldiene)-2-(6-morpholin-4-ylpyridin-3-yl)aminoacetohydrazide (10)

Yield (3.33 g, 64 %); m.p. 168–169 °C; IR (KBr, v, cm⁻¹): 3,283 (2NH), 1,699 (C=O), 1,588 (C=N), 1,116 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.34 (bs, 4H, N–2CH₂), 3.81 (d, 4H, O–2CH₂, J = 4.8 Hz), 4.87 (s, 2H, CH₂), 5.65 (s, 1H, NH), 6.57 (d, 1H, CH, J = 8.6 Hz), 7.31 (m, 3H, arH), 7.44–7.57 (m, 6H, arH), 7.97 (d, 3H, arH, J = 8.6 Hz), 10.54 (s, 1H, NH); ¹³C NMR (DMSO-d₆, δ ppm): 41.19 (CH₂), 47.15 (N–2CH₂), 66.99 (O–2CH₂), arC: [126.99 (2CH), 129.47 (2CH), 130.21 (2CH), 130.57 (2CH), 130.84 (2CH), 135.64 (2C), 134.05 (2CH), 140.82 (C)], 125.83 (CH, tiyazol C-4), 152.30 (tiyazol C-2), 153.84 (tiyazol C-5), 192.20 (C=O); LC–MS: m/z (%) 521.25 [M]^+ (45), 215.45 (65), 165.45 (75); Anal.calcd (%) for C₂₅H₂₅ClN₇O₂S: C, 59.94; H, 4.84; N, 16.13, S, 6.15. Found: C, 59.85; H, 4.78; N, 16.22; S, 6.18.

**Synthesis of compound 11**

A solution of compound 9 (10 mmol) in ethanol:water (1:1) was refluxed in the presence of 2N NaOH for 3 h, then, the resulting solution was cooled to room temperature, and acidified to pH 4 with 37 % HCl. The precipitate formed was filtered off, washed with water, and recrystallized from ethyl acetate to afford the desired compound.

5-\{[6-Morpholin-4-ylpyridin-3-yl]methyl\}-4-phenyl-4H-1,2,4-triazole-3-thiol (11)

Yield (3.17 g, 87 %): m.p. 165–166 °C; IR (KBr, v, cm⁻¹): 3,327 (NH), 3,093 (Ar CH), 2,857 (SH), 1,451 (C=N), 1,115 (C=O); ¹H NMR (DMSO-d₆, δ ppm): 3.17 (s, 4H, N–2CH₂), 3.66 (s, 4H, O–2CH₂), 4.06 (d, 2H, CH₂, J = 2.2 Hz), 5.51 (bs, 1H, NH), 6.68 (d, 1H, arH, J = 6 Hz), 6.81 (d, 1H, arH, J = 4.0 Hz), 7.44 (bs, 2H, arH), 7.52 (bs, 4H, arH), 13.91 (s, 1H, SH); ¹³C NMR (DMSO-d₆, δ ppm): 38.90–41.41 (DMSO-d₆+CH₃), 47.27 (N–2CH₂), 66.72 (O–2CH₂), arC: [108.81 (CH), 124.04 (2CH), 128.74 (2CH), 130.05 (2CH), 132.70 (CH), 134.16 (C), 137.63 (C), 151.06 (C), 153.48 (triazole C-3), 168.73 (triazole C-2); LC–MS: m/z (%) 368.22 [M]^+ (62), 165.45 (80); Anal.calcd (%) for C₁₈H₁₈N₉O₂S: C, 58.68; H, 5.47; N, 22.81, S, 8.70. Found: C, 58.72; H, 5.42; N, 22.80; S, 8.82.

**Synthesis of compound 12**

Concentrated sulfuric acid (64 mmol) was added into compound 9 (10 mmol) drop by drop under stirring, and the reaction content was stirred in an ice bath for 15 min. The mixture was allowed to reach to room temperature and stirred for an additional 3 h. Then, the resulting solution was poured into ice-cold water and made alkaline to pH 8 with ammonia. The precipitated product was filtered, washed with water, and recrystallized from ethanol to afford the desired product.

 Springer
5-[(6-Morpholin-4-ylpyridin-3-yl)methyl]-N-phenyl-1,3,4-thiadiazol-2-amine (12)

Yield (2.13 g, 58%); m.p. 172–173 °C; IR (KBr, v, cm⁻¹): 3,252 (2NH), 3,077 (Ar CH), 1,599 (C= N), 1,121 (C–O); ¹H NMR (DMSO-d₆, δ ppm): 3.49 (bs, 4H, N–2CH₂), 3.66 (bs, 4H, O–2CH₂), 4.49 (s, 2H, CH₂), 6.04 (bs, 1H, NH), 7.26–7.34 (m, 4H, arH), 7.54–7.66 (m, 4H, arH), 10.23 (s, 1H, NH); ¹³C NMR (DMSO-d₆, δ ppm): 34.63 (CH₂), 47.18 (N–2CH₂), 66.64 (O–2CH₂), ar C: [107.12 (CH), 126.52 (C), 129.52 (CH), 130.02 (CH), 132.84 (CH), 108.79 (CH), 121.52 (CH), 124.15 (CH), 125.19 (CH), 126.52 (C), 129.52 (CH), 130.02 (CH), 132.84 (CH), 138.32 (C), 148.02 (C), 152.30 (thiazolidine C-2), 158.39 (C=O); LC–MS: [M]⁺ (56), 137.53 (C), 141.31 (C), 153.50 (C), 161.75 (thiadiazole C-5), 165.11 (thiadiazole C-2); LC–MS: m/z (%) 368.45 [M]⁺ (56), 165.45 (85); Anal. calcd (%) for C₁₈H₂₀N₆O₃S: C, 56.32; H, 5.20; N, 19.70, S, 7.52. Found: C, 58.74; H, 5.55; N, 22.85; S, 8.75.

Synthesis of compound 13

Ethyl bromoacetate was added to the solution of compound 9 in absolute ethanol (10 mmol), and the mixture was refluxed in the presence of dried sodium acetate (16.4 g in 200 mmol) for 9 h. Then, the mixture was cooled to room temperature, poured into ice-cold water under stirring, and left overnight in cold. The formed solid was filtered, washed with water three times, and recrystallized from benzene-petroleum ether (1:2) to afford the pure compound.

2-[(6-Morpholin-4-ylpyridin-3-yl)amino]-N’-(4-oxo-3-phenyl-1,3-thiazolidin-2-ylidene)acetohydrazide (13)

Yield (3.33 g, 45%); m.p. 201–202 °C; IR (KBr, v, cm⁻¹): 3,326 (2NH), 1,746 (2C=O), 1,492 (C= N), 1,119 (C–O); ¹H NMR (DMSO-d₆, δ ppm): 3.17 (bs, 4H, N–2CH₂), 3.67 (bs, 4H, O–2CH₂), 3.86 (d, 2H, CH₂, J = 3.8 Hz), 4.18 (s, 2H, S–CH₂), 5.74 (bs, 1H, NH), 6.89–7.16 (m, 5H, arH), 7.32–7.38 (m, 3H, arH), 10.86 (s, 1H, NH); ¹³C NMR (DMSO-d₆, δ ppm): 30.61 (NH–CH₂), 45.58 (thiazolidine–CH₂), 56.28 (N–2CH₂), 66.64 (O–2CH₂), ar C: [107.12 (CH), 108.79 (CH), 121.52 (CH), 124.15 (CH), 125.19 (CH), 126.52 (C), 129.52 (CH), 130.02 (CH), 132.84 (CH), 138.32 (C), 148.02 (C), 152.30 (thiazolidine C-2), 158.39 (thiazolidine C-4), 170.94 (C=O); LC–MS: m/z (%) 426.52 [M]⁺ (52), 215.86 (64), 165.42 (74); Anal. calcd (%) for C₂₆H₂₆N₆O₃S: C, 56.32; H, 5.20; N, 19.70, S, 7.52. Found: C, 56.42; H, 5.32; N, 19.65; S, 7.62.

Antimicrobial activity

All test microorganisms were obtained from the Hifzissihha Institute of Refik Saydam (Ankara, Turkey) and were as follows: *Escherichia coli* (*E. coli*) ATCC35218, *Yersinia pseudotuberculosis* (*Y. pseudotuberculosis*) ATCC911, *Pseudomonas aeruginosa* (*P. aeruginosa*) ATCC43288, *Enterococcus faecalis* (*E. faecalis*) ATCC29212, *Staphylococcus aureus* (*S. aureus*) ATCC25923, *Bacillus cereus* (*B. cereus*) 709 Roma, *Mycobacterium smegmatis* (*M. smegmatis*) ATCC607, *Candida albicans* (*C. albicans*) ATCC60193, and *Saccharomyces cerevisiae* (*S. cerevisia*) RSKK 251. All the newly synthesized compounds were weighed and dissolved in hexane to prepare extract stock solution of 20.000 microgram/milliliter (µg/mL).

The antimicrobial effects of the substances were tested quantitatively in respective broth media by means of double microdilution, and the minimal inhibition concentration (MIC) values (µg/mL) were determined. The antibacterial and antifungal assays were performed in Mueller–Hinton broth (MH) (Difco, Detroit, MI) at pH 7.3 and buffered Yeast Nitrogen Base (Difco, Detroit, MI) at pH 7, respectively. The micro dilution test plates were incubated for 18–24 h at 35 °C. Brain Heart Infusion broth (BHI) (Difco, Detroit, MI) was used for *M. smegmatis*, and incubated for 48–72 h at 35 °C (Woods et al., 2003). Ampicillin (10 µg) and fluconazole (5 µg) were used as standard antibacterial and antifungal drugs, respectively. Dimethylsulfoxide with dilution of 1:10 was used as solvent control. The results are presented in Table 1. Urease inhibitory activity was determined according to Van Slyke and Archibald (Van Slyke and Archibald, 1944), and the results are shown in Table 2.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

Adil M, Aslama S, Mahmoodb S, Shahidc M, Saedeb A, Iqbalala J (2011) Synthesis, biological assay in vitro and molecular docking studies of new Schiff base derivatives as potential urease inhibitors. Eur J Med Chem 46:5473–5479

Aktay G, Tozkoparan B, Ertan M (2009) Investigation of antioxidant properties of some 6-(α-aminobenzyl)thiazolo[3,2-b]-1,2,4-triazole-5-ol compounds. J Enzym Inhib Med Chem 24:898–902

Amtul Z, Rahman A, Siddiqia RA, Choudhary MI (2002) Chemistry and properties of some 6-(6-morpholinoacetyl-2,6-diarylpiperidin-4-ones. Eur J Med Chem 37:851–860

Aridoss G, Balasubramanian GAS, Parthiban P, Kabilan S (2007) Amtul Z, Rasheed M, Choudhary MI, Supino R, Khan KM, Rahman A (2004) Kinetics of novel competitive inhibitors of urease enzymes by a focused library of oxadiazoles/thiadiazoles and docking studies of new Schiff base derivatives as potential urease inhibitors. Eur J Med Chem 46:5473–5479

Andres CJ, Bronson JJ, Andrea SVD, Deshpande MS, Falk PJ, Grant-Young KA, Harte WE, Ho HT, Misco PF, Robertson JG, Stock D, Sun Y, Walsh AW (2000) 4-Thiazolidinones: novel inhibitors of the bacterial enzyme mBar. Bioorg Med Chem Lett 10:715–717

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Ashiralieva A, Kleiner D (2003) Polyhalogenated benzo- and naphthoquinones are potent inhibitors of plant and bacterial ureases. FEBS Lett 555:367–370
Ashok M, Holla BS, Poojary B (2007) Convenient one pot synthesis and antimicrobial evaluation of some new Mannich bases carrying 4-methylthiobenzyl moiety. Eur J Med Chem 42:1095–1101
Bachmeier KL, Williams AE, Warmington JR, Bang SS (2002) Urease activity in microbiologically-induced calcite precipitation. J Biotechnol 93:171–181
Barreca ML, Chimirri A, Luca LD, Monforte A, Monforte P, Rao A, Zappala M, Balzarini J, De Clercq E, Pannecoque C, Witvrouw M (2001) Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett 11:1793–1796
Bayrak H, Demirbas A, Demirbas N, Alpay Karaoglu S (2009b) Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities. Eur J Med Chem 44:4362–4366
Bayrak H, Demirbas A, Alpay Karaoglu S, Demirbas N (2009b) Synthesis of some new 1,2,4-triazoles, their Mannich and Schiff bases and evaluation of their antimicrobial activities. Eur J Med Chem 44:1057–1066
Bayrak H, Demirbas A, Demirbas N, Alpay Karaoglu S (2010a) Cyclization of some carbothioamide derivatives containing antipyrine and triazole moieties and investigation of their antimicrobial activities. Eur J Med Chem 45:4726–4732
Bayrak H, Demirbas A, Bektas H, Alpay Karaoglu S, Demirbas N (2010b) Synthesis and antimicrobial activities of some new 1,2,4-triazole derivatives. Turk J Chem 34:835–846
Bekircan O, Ozem T, Gumrukcuoglu N, Bektas H (2008) Synthesis and antioxidant properties of some new 3-(4-chlorophenyl)-5-(pyrindin-4-yl)-4H-1,2,4-triazole derivatives. Z Naturforsch 63:548–554
Bektas H, Karray N, Sahin D, Demirbas A, Alpay Karaoglu S, Demirbas N (2010) Synthesis and antimicrobial activities of some new 1,2,4-triazole derivatives. Molecules 15:2427–2438
Bektas H, Demirbas A, Demirbas N, Alpay Karaoglu S (2012) Synthesis and biological activity studies of new hybrid molecules containing tryp Hampton mide. Med Chem Res 21:212–223
Bonde CG, Gaikwad NJ (2004) Synthesis and preliminary evaluation of some pyrazine containing thiazolines and thiazolindiones as antimicrobial agents. Bioorg Med Chem 12:2151–2161
Cai S, Li QS, Borchardt RT, Kuczera K, Schowen RL (2007) The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi. Bioorg Med Chem 15:7281–7287
Capan G, Ulusoy N, Ergenc N, Kiraz M (1999) New 6-phenylimidazo[2,1-b]thiazole derivatives: synthesis and antifungal activity. Monatsh Chem 130:1399–1407
Cheng K, Zheng QZ, Zhu HL (2009) Syntheses, structures and urea inhibitory activities of mononuclear cobalt(III) and 1D cobalt(II) complexes with ligands derived from 3-formylsalicylic acid. Inorg Chem Commun 12:1116–1119
Colena AS, Missetbrook TH, Arce A, Mingot JI, Diz EA, Vallem J (2008) An inhibitor of urease activity effectively reduces ammonia emissions from soil treated with urea under Mediterranean conditions. Agric Ecosyst Environ 126:243–249
Cui Y, Deng Y, Yang Y, Zhang S, Ji R (2005) Syntheses and antibacterial activity of a series of 3-(pyridine-3-yl)-2-oxazolidinone. Eur J Med Chem 40:209–214
Das B, Rudra S, Yadav A, Ray A, Rao AVSR, Srinivas ASSV, Saini S, Shukla S, Pandya M, Bhateta P, Malhotra S, Mathur T, Arora SK, Rattan A, Metha A (2005) Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid. Bioorg Med Chem Lett 15:4261–4267
Demirbas A, Sahin D, Demirbas N, Alpay Karaoglu S (2009) Synthesis of some new 1,3,4-thiadiazol-2-ylmethyl-1,2,4-triazole derivatives and investigation of their antimicrobial activities. Eur J Med Chem 44:2896–2903
Dixit PP, Nair PS, Patil VJ, Jain S, Arora SK, Sinha N (2005) Synthesis and antibacterial activity of novel (un)substituted benzo triazoyl oxazolidinone derivatives. Bioorg Med Chem Lett 15:3002–3005
Dixit PP, Patil VJ, Nair PS, Jain S, Sinha N, Arora SK (2006) Synthesis of 1-[3-(4-benzotriazol-1-yl-2-thio-furan)-2-oxo oxazolidin-5-ylmethyl]-3-substituted-thiourrea derivatives as antituberculosis agents. Eur J Med Chem 41:423–428
Domínguez MJ, Sammartín C, Font M, Palop JA, Francisco SS, Urrutia O, Houdusse F, Garcia-Ma J (2008) Design, synthesis, and biological evaluation of phosphoramidate derivatives as urease inhibitors. J Agric Food Chem 56:3721–3731
Duruki JO, Ogwugbu MO, Ekwuruwa JN (2007) Heavy metal pollution and human biotoxic effects. Int J Phys Sci 2:112–118
Dye C, Phil D (2006) Global epidemiology of tuberculosis. The Lancet 367:938–940
Dye C, Williams BG (2009) Slow elimination of multidrug-resistant tuberculosis. Transl Med 1(3):3–8
El-Gaby MSA, El-Hag Ali GAMMA, El-Maghraby A, Abd El-Rahman MT, Helal MHM (2009) Synthesis, characterization and in vitro antimicrobial activity of novel 2-thiooxo-4-thiazolidinones and 4,4′-bis(2-thiooxo-4-thiazolidinone-3-yl) diphenyl sulfones. Eur J Med Chem 44:4148–4152
Gage JG, Perrault WP, Poel TJ, Thomas RC (2000) Stereodivergent synthesis of sulfide-containing oxazolidinone antibiotics. Tetrahedron Lett 41:4301–4305
Giere R, Cantos-Llopant C, Amat M, Bosch J, del Castillo JC, Huguet (2006) New potential antibacterials: a synthetic route to N-aryloxazolidinone/3-arylethylhydroxyoxazoline hybrids. Bioorg Med Chem Lett 16:529–531
Gupta A, Unadkat JD, Mao Q (2007) Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci 96:3226–3235
Hancu G, Gaspar A, Gyeresi A (2007) Separation of 1,4-benzodiazepines by micellar electrokinetic chromatography. J Biochem Biophys Methods 69:251–259
Ito Y, Shibata K, Hongo A, Ecabat Kinosita M (1998) Sodium, a locally acting antibiotic drug, inhibits urease activity of Helicobacter pylori. Eur J Pharm 345:193–198
Khan KM, Wadood A, Ali M, Ullah Z, Ul-Haq Z, Lodhi MA, Khan M, Pervez S, Choudhary MI (2010a) Identification of potent urease inhibitors via ligand- and structure-based virtual screening and in vitro assays. J Mol Graph Model 28:792–798
Khan L, Ali S, Hameed S, Rama NH, Hussain MT, Wadood A, Uddin R, Ul-Haq Z, Khan A, Ali S, Choudhary MI (2010b) Synthesis, antioxidant activities and urease inhibition of some new 1,2,4-triazole and 1,3,4-thiadiazole derivatives. Eur J Med Chem 45:5200–5207
Koca M, Servi S, Kirilmis C, Ahmedzade M, Kazaz C, Özbek B, Ötük G (2005) Synthesis and antimicrobial activity of some novel derivatives of benzofuran-2yl)-3-phenyl-3-methylcyclobutyl ketone. Eur J Med Chem 40:1351–1358
Kot M, Zaborska W, Orłotka K (2001) Inhibition ofjack bean urease by (N-(n-butyl)-thiophosphorothriamide and (N-(n-butyl)-phosphorothriamide: determination of the inhibition mechanism. J Enzym Inhib Med Chem 16:507–516
Kot M, Karcz W, Zaborska W (2010) 5-Hydroxy-1,4-naphthoquinone (juglone) and 2-hydroxy-1,4-naphthoquinone (lawsonite) influence on jack bean urease activity: elucidation of the difference in inhibition activity. Bioorg Chem 38:132–137
Krajewska B (2009) Ureases I. Functional, catalytic and kinetic properties: a review. J Mol Catal B Enzym 59:9–21
Kreybig T, Preussmann R, Schmidt W (1968) Chemical constitution and teratogenic effect in rats. I. Carbonic acid amides, carbonic
acid hydrazides and hydroxamic acids. Arzneim Forsch 18: 645–657
Küçükgüzeli SG, Oruç EE, Rollas S, Şahin F, Özbek A (2002) Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. Eur J Med Chem 37:197–206
Matsumara S, Shibata H, Ishikawa F, Yokokura T, Takahashi M, Sugimura T (2003) Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun 310:715–719
Muri EMF, Mishra H, Avery MA, Williamson JS (2003) Design and synthesis of heterocyclic hydroxamic acid derivatives as inhibitors of Helicobacter pylori urease. Synth Commun 33:1977–1995
National Committee for Clinical Laboratory Standard (1999) Methods for determining bactericidal activity of antimicrobial agents, App Guid NCCLS, Willanova, M26-A: 18–19
Panneerselvam P, Nair RR, Vijayalakshimi G, Subramanian EH, Sridhar SK (2005) Synthesis of Schiff bases of 4-(4-aminophenyl)-morpholine as potential antimicrobial agents. Eur J Med Chem 40:225–229
Rao BM, Sangaraju S, Srinivasu MK, Madhavan P, Devi ML, Kumar PR, Candrasekhar P, Arpitha C, Balaji TS (2006) Development and validation of a specific stability indicating high performance liquid chromatographic method for rizatriptan benzoate. J Pharm Biomed Anal 41:1146–1151
Raparti V, Chitre T, Bothara K, Kumar V, Dangre S, Khachane C, Gore S, Deshmukh B (2009) Novel 4-(morpholin-4-yl)-N'-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations. Eur J Med Chem 44:3954–3960
Sahin D, Bayrak H, Demirbas A, Demirbas N, Alpay-Karaoglu S (2011) Design and synthesis of some azole derivatives as potential antimicrobial agents. Med Chem Res. doi: 10.1007/s00044-012-9992-2
Schiller SD, Fung HB (2007) Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther 29:1862–1886
Shi DH, You ZL, Xu C, Zhang Q, Zhu HL (2007) Synthesis, crystal structure and urease inhibitory activities of Schiff base metal complexes. Inorg Chem Commun 10:404–406
Shin JE, Kim JM, Bae EA, Hyun YJ, Kim DH (2005) In Vitro Inhibitory Effect of Flavonoids on Growth, Infection and Vacuolation of Helicobacter pylori. Planta Med 71:197–201
Srivastava BK, Jain MR, Solanki M, Soni R, Valani D, Gupta S, Mishra B, Takale V, Kapadnis P (2008) Synthesis and in vitro antibacterial activities of novel oxazolidinones. Eur J Med Chem 43:683–693
Van Slyke DD, Archibald RM (1944) Monometric, titrimetric and colorimetric methods for measurements of urease activity. J Biol Chem 154:623–642
Vicini P, Geronikaki A, Incerti M, Zani F, Dearden J, Hewitt M (2008) 2-Heteroarylilmino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidine-4-thiazolidinones with antimicrobial activity: synthesis and structure–activity relationship. Bioorg Med Chem 16:3714–3724
Weidner-Wells MA, Broggs CM, Foleno BD, Melton J, Bush K, Goldshmidt RM, Hlasta D (2002) Novel piperidinyloxy oxazolidinone antibacterial agents. Diversification of the N-substituent. Bioorg Med Chem 10:2345–2351
Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyrffer GE, Ridderhof JC, Wallace RJ, Warren NC, Wittebsky FG (2003) Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. App Stand NCCLS document M24-A: 18–23
Wyrzykiewicz E, Wendzonka M, Kedzi B (2006) Synthesis and antimicrobial activity of new (E)-4-[piperidino (4'-methylpiperidino-, morpholino-) N-alkoxy]stilbenes. Eur J Med Chem 41: 519–525
Yamashita Y, Kawada SZ, Nakaro H (1990) Competitive binding of 7-substituted-2,3-dichlorodibenzo-p-dioxins with human placental Ah receptor-A QSAR analysis. Biochem Pharmacol 39: 737–744
You ZL, Zhang L, Shi DH, Wang XL, Li XF, Ma YP (2010) Synthesis, crystal structures and urease inhibitory activity of copper(II) complexes with Schiff bases. Inorg Chem Comm 13:996–998
Yu LT, Ho MT, Chang CY, Yang TK (2007) Asymmetric zinc-Reformatsky reaction of evans chiral imide with acetophenones and its application to the stereoselective synthesis of triazole antifungal agents. Tetrahedron Asymmetry 18:949–962
Zalavadiya P, Tala S, Akbari J, Joshi H (2009) Multi-component synthesis of dihydropyrimidines by iodine catalyst at ambient temperature and in vitro antimycobacterial activity. Arch Pharm 342:469–475
Zheng QZ, Cheng K, Zhang XM, Liu K, Jiao QC, Zhu HL (2010) Synthesis of some N-alkyl substituted urea derivatives as antibacterial and antifungal agents. Eur J Med Chem 45: 3207–3212